Clinical Trial Update: Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and preliminary efficacy of combining IMO-2125 with ribavirin in treatment-naïve genotype 1 hepatitis C patients; results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• IMO-2125 (IMO-2125)
• Ribavirin (ribavirin)

Snippet

Sponsor: Idera Pharmaceuticals, Inc. | Conditions: Hepatitis C, Treatment Naïve, Genotype 1 Patients | Phase 1 | Status: COMPLETED | Results posted: 2019-02-15